Answers are grounded in this paper and cite their sources.
Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
No takes yet. Share an insight, caveat, or question.
Andreu‐Vieyra et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: